Stryker Stock (NYSE:SYK), Trade Ideas

Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

News

Health Care

Markets

Trading Ideas

General

Boston Scientific Corporation (NYSE: BSX) has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 (Sell) currently.

Boston Scientific (BSX) Faces Rising Costs, Competition

GMED

Globus Medical (NYSE: GMED) continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company is expanding in the overseas markets through the expansion of direct and distributor sales force.

Globus Medical (GMED) Gains From New Launches Amid Macro Issues

Financial,Analyst,Using,Smartphone,With,Real-time,Stocks,,Commodities,And,Market

Equities

Fintech news covering the emerging Financial Technology services sector

Fintech

Tech

AIQUY

ASML

AVGO

BIDU

ENGIY

WKCMY

In a recent report, global wealth manager UBS has identified the sectors that are likely to drive the next wave of technological innovation and the stocks that stand to benefit.

Which Stocks Will Dominate The Future Of Tech? UBS Shares Its Top Picks In AI, Healthtech, Greentech, And Fintech

Stryker Corp

SOLITON SYSTEMS KK ORD by Soliton Systems

Soliton Systems KK

SKY NETWORK TV by Sky Network Television Ltd.

Options

Stryker Unusual Options Activity For April 19

<p>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 20 years by 2.32% on an annualized basis producing an average annual return of 9.99%. Currently, Stryker has a market capitalization of $128.55 billion. </p>
<p><strong>Buying $100 In SYK:</strong> If an investor had bought $100 of SYK stock 20 years ago, it would be worth <strong>$675.76</strong> today based on a price of $337.87 for SYK at the time of writing.</p>
<h3>Stryker's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713382216_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Stryker Stock In The Last 20 Years

<p>RBC Capital  analyst Shagun Singh   maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $360 to $386.</p>


Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Stryker, Raises Price Target to $386

<p>TD Cowen  analyst Joshua Jennings   maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $365 to $400.</p>


TD Cowen Maintains Buy on Stryker, Raises Price Target to $400

<p><strong>Boston Scientific Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>) has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 (Sell) currently.</p>
<p>The industry-wide trend of challenging macroeconomic conditions in the form of inflation, disruptions in economic activity, global supply chains and labor markets, volatile financial market dynamics and significant volatility in price and availability of goods and services are putting pressure on Boston Scientific&#39;s profitability. Further, international conflicts, including the Russia-Ukraine war and tensions between China and Taiwan, have increased cybersecurity risks on a global basis. With sustained macroeconomic pressure, the company may struggle to keep its operating expenses in check.<br />
In the fourth quarter of 2023, the company reported a 13.4% rise in the cost of products sold and an 18.6% rise in selling, general and administrative expenses. Adjusted operating margin contracted 22 basis points (bps) to 22.1% in the reported quarter.</p>
<p>With Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the last few quarters, as in the case of other important MedTech players, too.<br />
In 2023, the company faced an approximate 80 bps headwind from foreign exchange on revenues.</p>
<p>Further, the presence of a large number of players has made the medical devices market highly competitive. The company operates in several markets, including cardiovascular, CRM, endosurgery and neuromodulation, where it faces competition from large, well-capitalized companies such as Johnson &amp; Johnson, Abbott, Medtronic, Stryker, Smith &amp; Nephew and Edwards Lifesciences, apart from several other smaller companies.</p>
<div class="chart_embed">
<h3>Boston Scientific Corporation Price</h3>
<p><a href="https://www.zacks.com/stock/chart/BSX/fundamental/price?icid=chart-BSX-fundamental/price"><img alt="Boston Scientific Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/2c/1712746810.png" style="height:251px; width:538px" title="" /> </a></p>
<p>Boston Scientific Corporation price | Boston Scientific Corporation Quote</p>
</div>
<p>On a positive note, Boston Scientific has been continuing with its expansion of operations across different geographies outside the United States. Within its international regions, the company is putting additional efforts to expand its foothold in emerging markets (which are defined as all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada). These hold strong growth potential based on their economic conditions, healthcare sectors and global capabilities.</p>
<p>We are also impressed with Boston Scientific&#39;s recent acquisitions that have added numerous products (though many are under development) with immense potential. This, in turn, should help boost the top line in the long term.<br />
In December 2023, Boston Scientific announced its plans to acquire Axonics, a medical technology company that offers innovative devices to treat urinary and bowel dysfunction. With this $3.7-billion acquisition, the company expects to expand its differentiated technologies portfolio within Urology.</p>
<p><strong>Key Picks</strong></p>
<p>Some better-ranked stocks from the broader medical space are&nbsp;<strong>Stryker Corporation</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>), <strong>Cencora, Inc.</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cor#NYSE">COR</a>) and&nbsp;<strong>Cardinal Health</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>).</p>
<p>Stryker, carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2023 adjusted EPS of $3.46, beating the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%.</p>
<p>Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&amp;P 500&#39;s 9.9%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 5.1%.</p>
<p>Cencora, carrying a Zacks Rank #2, reported first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.</p>
<p>COR has an earnings yield of 5.75% compared with the industry&#39;s 1.85%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 6.7%.</p>
<p>Cardinal Health, carrying a Zacks Rank #2, reported second-quarter fiscal 2024 adjusted earnings of $1.82, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%.</p>
<p>CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry&#39;s 11.8% growth. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.</p>
<p><a href="https://www.zacks.com/stock/news/2253274/boston-scientific-bsx-faces-rising-costs-competition?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2253274">To read this article on Zacks.com click here.</a></p>


<p><strong>Globus Medical </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gmed#NYSE">GMED</a>) continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company is expanding in the overseas markets through the expansion of direct and distributor sales force. Yet, we are worried about a challenging macroeconomic scenario that continues to plague Globus Medical&#39;s profit margins. It has a Zacks Rank #3 (Hold) at present.</p>
<p>GMED is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories, and unique surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures.<br />
The company is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings. Over the past couple of quarters, this business has registered above-market growth, driven by competitive rep recruiting from prior quarters and robotic pull-through.<br />
In the fourth quarter, Legacy Globus&#39; musculoskeletal revenues surged 11.8%. The growth was led by the company&#39;s U.S. and international spine businesses, as well as continued share growth within trauma.<br />
Earlier, Globus Medical launched three new products &mdash; REFLECT, MARVEL and Ossifuse. The company continues to make significant progress in launching its prone, lateral patient positioning system. As the company moves into 2024, it anticipates a strong cadence of product launches throughout the Musculoskeletal portfolio.</p>
<div class="chart_embed">
<h3>Globus Medical, Inc. Price</h3>
<p><a href="https://www.zacks.com/stock/chart/GMED/fundamental/price?icid=chart-GMED-fundamental/price"><img alt="Globus Medical, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/63/1712230792.png" style="height:251px; width:538px" title="" /> </a></p>
<p>Globus Medical, Inc. price | Globus Medical, Inc. Quote</p>
</div>
<p>Globus Medical merged its business with NuVasive. The combined company forms a global musculoskeletal business, focused on rapid innovation, addressing unmet clinical needs and improving offerings to surgeons and patients. It capitalizes on GMED&#39;s complementary commercial organization and should allow the company to accelerate its globalization strategies to increase customer reach and strengthen surgeon relationships.<br />
The combined company is working to bring the best-in-class technologies to create a differentiated and comprehensive procedural solution offering as part of its approach to address unmet clinical needs and support surgeons and patients. According to Globus Medical, both the companies&#39; operational footprints are highly complementary, allowing them to better leverage each other&#39;s manufacturing and supply-chain resources to increase internal production while reducing the amount of required stand-alone capital investment. This way, they can redirect investments and improve cash flow.<br />
In terms of the latest development, NuVasive stand-alone sales for the fourth quarter were up 2% on a pro forma basis. This was primarily driven by continued market penetration in the international spine with 14% growth, market re-entry of key technology of NuVasive Specialty Orthopedics delivering 26% gains, and strengthening NuVasive Clinical Services increasing 6% from the prior- year level.</p>
<p>On the flip side, Globus Medical, like other industry players, is currently fighting negative trends in the global economy, including interest rate fluctuations, increases in inflation and financial market volatility. These factors are adversely impacting the company&#39;s operations and financial performance. The global inflation, in particular, has led to a significant rise in the cost of raw materials for the company. In the fourth quarter, GMED witnessed a 276.1% surge in the cost of goods sold.<br />
These macroeconomic factors, along with the rising wage and raw material costs, are also leading to a significant escalation in the company&#39;s operating expenses. SG&amp;A expenses in the reported quarter were up 107.3% from the year-ago quarter&#39;s level. Research and development expenses increased 167.9% year over year.</p>
<p>Meanwhile, the presence of a large number of players made the musculoskeletal devices market intensely competitive. The orthopedic industry, in particular, is highly competitive with the presence of more prominent players like Zimmer Biomet, Stryker, Johnson &amp; Johnson&#39;s DePuy, Smith &amp; Nephew and Medtronic. Globus Medical needs to constantly introduce or acquire new products to withstand the competitive pressure and maintain its market share.</p>
<h3>Key Picks</h3>
<p>Some better-ranked stocks in the broader medical space are <strong>DaVita</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), <strong>Stryker </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) and <strong>Cardinal Health</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>). While DaVita presently sports a Zacks Rank #1 (Strong Buy), Stryker and Cardinal Health carry a Zacks Rank #2 (Buy) each.</p>
<p>DaVita&#39;s shares have risen 65.3% in the past year. Earnings estimates for DaVita have risen from $8.97 per share to $9.23 in 2024 and from $9.77 to $10.01 in 2025 in the past 30 days.</p>
<p>DVA&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 35.6%. In the last reported quarter, it posted an earnings surprise of 22.2%.</p>
<p>Estimates for Stryker&#39;s 2024 earnings per share (ETF:EPS) have remained constant at $11.86 in the past 30 days. Shares of the company have risen 21.5% in the past year compared with the industry&#39;s growth of 4,6%.</p>
<p>SYK&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%. In the last reported quarter, it delivered an earnings surprise of 5.8%.</p>
<p>Estimates for Cardinal Health&#39;s 2024 EPS have moved up to $7.29 from $7.28 in the past 30 days. Shares of the company have surged 45% in the past year compared with the industry&#39;s 11.7% growth.</p>
<p>CAH&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%. In the last reported quarter, it delivered an earnings surprise of 16.7%.</p>
<p><a href="https://www.zacks.com/stock/news/2250489/globus-medical-gmed-gains-from-new-launches-amid-macro-issues?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2250489">To read this article on Zacks.com click here.</a></p>


<p>Evercore ISI Group  analyst Vijay Kumar   maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $340 to $370.</p>


Evercore ISI Group Maintains Outperform on Stryker, Raises Price Target to $370

<p>Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Stryker and provided 12-month price targets. The average target is $361.11, accompanied by a high estimate of $406.00 and a low estimate of $345.00. This upward trend is apparent, with the current average reflecting a 6.52% increase from the previous average price target of $339.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1712163627_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Stryker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$406.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$362.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$345.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Jason Wittes</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$348.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Kyle Rose</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$364.00</td>
<td>$336.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$345.00</td>
<td>$315.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stryker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stryker compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Stryker's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Stryker's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SYK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Stryker analyst ratings.</strong></a></p>
<h2>Get to Know Stryker Better</h2>
<p>Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.</p>
<h3>Stryker's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Stryker displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>11.78%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>19.66%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Stryker's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>6.26%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Stryker's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.93%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Stryker's debt-to-equity ratio surpasses industry norms, standing at <strong>0.7</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Stryker: Insights From 9 Financial Analysts

<p>Citigroup  analyst Joanne Wuensch   maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $362 to $406.</p>


Citigroup Maintains Buy on Stryker, Raises Price Target to $406

<p>In the current session, the stock is trading at $351.79, after a <strong>0.63%</strong> spike. Over the past month, <strong>Stryker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>)</strong> stock increased by <strong>1.24%</strong>, and in the past year, by <strong>26.87%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1711558811_0.png" alt="Past Year Chart" /></p>

<h3>How Does Stryker P/E Compare to Other Companies?</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>52.9</strong> in the Health Care Equipment &amp; Supplies industry, Stryker Inc. has a lower P/E ratio of <strong>42.47</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1711558811_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

Price Over Earnings Overview: Stryker

<p><strong>Stryker's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) short percent of float has fallen 12.03% since its last report. The company recently reported that it has <strong>4.18 million shares sold short</strong>, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.32 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Stryker Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711557019_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Stryker has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Stryker's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Stryker's peer group average for short interest as a percentage of float is 4.19%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Looking Into Stryker's Recent Short Interest

<p>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 20 years by 2.91% on an annualized basis producing an average annual return of 10.81%. Currently, Stryker has a market capitalization of $134.09 billion. </p>
<p><strong>Buying $100 In SYK:</strong> If an investor had bought $100 of SYK stock 20 years ago, it would be worth <strong>$792.06</strong> today based on a price of $352.62 for SYK at the time of writing.</p>
<h3>Stryker's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711395019_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In Stryker 20 Years Ago Would Be Worth This Much Today

<p>In a recent report, global wealth manager <strong>UBS</strong> identified the sectors likely to drive the next wave of technological innovation and the stocks that stand to benefit.</p>
<p><b>What Happened: </b>UBS has pinpointed artificial intelligence (AI), cybersecurity, health tech, Greentech, and fintech as the sectors that will produce the &#8220;next big thing&#8221; in tech. The bank has selected 29 companies that are expected to experience &#8220;superior&#8221; earnings growth compared to the market, driven by &#8220;positive, durable structural trends,&#8221; CNBC <a href="https://www.cnbc.com/2024/03/18/next-big-thing-in-tech-ubs-names-stocks-to-own-for-the-longer-term.html">reported</a> on Sunday.</p>
<p>"Collectively, we see industry leaders for 2030 emerging from these sectors," said UBS in a March 14 report.&nbsp;</p>
<p>Among the companies on UBS&#8217; list are:</p>
<ul>
<li><strong>McKesson Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>): The company&#8217;s expansion into data-driven services across the U.S. healthcare value chain will cause UBS to be bullish in the future.</li>
</ul>
<ul>
<li><strong>Baidu</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>): UBS sees Baidu&#8217;s expertise in AI and machine learning, particularly in its non-advertising businesses like autonomous driving and cloud, as potential long-term growth drivers.</li>
<li><strong>Stryker</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): UBS notes Stryker&#8217;s growth in its core orthopedic markets, particularly in robotic surgery, as a strong indicator of future performance.</li>
</ul>
<ul>
<li><strong>ASML <strong>Holding</strong></strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>): UBS predicts the Dutch semiconductor firm will outgrow its peers due to the continued rise in lithography capital expenditure spending.</li>
</ul>
<ul>
<li><strong>Broadcom</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): UBS highlights Broadcom&#8217;s market-leading position in semiconductor design and its potential to tap into the structural demand for 5G-related services, data center storage, and industrial applications.</li>
</ul>
<p><em>See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37765365/dont-be-afraid-top-crypto-analyst-shares-his-plan-to-buy-dogecoin-shiba-inu-and-oth?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Don&#8217;t Be Afraid&#8217;: Top Crypto Analyst Shares His Plan To Buy Dogecoin, Shiba Inu, And Other Altcoins For Potential 5X Gains Post Correction</a></em></p>
<p>Other companies on the list include <strong>Intercontinental Exchange</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), <strong>Mastercard Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), <strong>Air Liquide</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AIQUY#OTC">AIQUY</a>), <strong>Engie</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ENGIY#OTC">ENGIY</a>), <strong>Wacker Chemie</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WKCMY#OTC">WKCMY</a>), <strong>ServiceNow</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), and <strong>Taiwan Semiconductor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).</p>
<p><strong>Why It Matters</strong>: The UBS report aligns with recent developments in the tech industry. For example, AI has been a hot topic, with experts like <strong>Jim Cramer</strong> expressing excitement about the <a href="https://www.benzinga.com/markets/equities/24/03/37769867/jim-cramer-pumped-up-about-nvidia-ceo-jensen-huangs-gtc-2024-speech-when-our-modern-day-davinci-">potential of AI</a> in Nvidia&#8217;s future. </p>
<p>However, other industry voices, such as <strong>Fidelity International</strong>, have suggested that investors look <a href="https://www.benzinga.com/markets/equities/24/03/37724250/nvidia-isnt-the-only-ai-contender-fidelity-suggests-investors-look-beyond-hot-ai-stocks-names-th">beyond the obvious choices</a>, like Nvidia, for AI investments. </p>
<p>Despite this, <strong>Glen Kacher</strong> of Light Street Capital has advised that it <a href="https://www.benzinga.com/markets/equities/24/03/37724593/way-too-early-expert-warns-as-investors-trading-out-of-nvidia-amd-microsoft-and-other-ai-stocks">may be too early to exit</a> the semiconductor market, suggesting that we are still at the beginning of the investment cycle for building an AI infrastructure. </p>
<p>This indicates that the tech sectors identified by UBS may indeed be the next big thing, with AI and semiconductors playing a crucial role.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37761475/dogecoin-killer-shiba-inu-burn-rate-defies-market-action-with-933-surge-daily-active-addre?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Dogecoin Killer&#8217; Shiba Inu Burn Rate Defies Market Action With 933% Surge, Daily Active Addresses Spike By 8%</a></em></p>
<p>Image Via Shutterstock </p>
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>
<p style="font-family: sans-serif;padding-top: 20px">
            Engineered by <span style="font-weight: bold;text-decoration: none;color: #225aa9;font-size: 1rem">Benzinga Neuro</span>, Edited by <span style="font-weight: bold;text-decoration: none;color: #225aa9;font-size: 1rem"><br />
                <u><a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Kaustubh Bagalkote</a></u><br />
            </span>
        </p>
<hr style="border: 0;height: 1px;background: #225aa9" />
<p style="font-family: sans-serif;padding-top: 20px">
            The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.<br />
            <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
        </p>
<hr style="border: 0;height: 5px;background: #225aa9" />
    </div>
</div>


<p>High-rolling investors have positioned themselves bearish on Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SYK often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for Stryker. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 40% bullish and 60% bearish. Among all the options we identified, there was one put, amounting to $39,000, and 9 calls, totaling $557,142.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $300.0 and $370.0 for Stryker, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Stryker's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Stryker's substantial trades, within a strike price spectrum from $300.0 to $370.0 over the preceding 30 days.</p>
<h3>Stryker Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1710532881_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/15/24</td>
<td>$320.00</td>
<td>$198.0K</td>
<td style="text-align: right;">412</td>
<td style="text-align: right;">9</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/15/24</td>
<td>$320.00</td>
<td>$99.0K</td>
<td style="text-align: right;">412</td>
<td style="text-align: right;">105</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$370.00</td>
<td>$51.9K</td>
<td style="text-align: right;">109</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/15/24</td>
<td>$340.00</td>
<td>$47.1K</td>
<td style="text-align: right;">471</td>
<td style="text-align: right;">142</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/15/24</td>
<td>$340.00</td>
<td>$39.2K</td>
<td style="text-align: right;">471</td>
<td style="text-align: right;">51</td>
</tr>
</tbody>
</table>
</p>
<h3>About Stryker</h3>
<p>Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.</p>
<p>After a thorough review of the options trading surrounding Stryker, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Stryker</h3>
<ul>
<li>Trading volume stands at 673,368, with SYK's price down by -0.84%, positioned at $352.66.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 45 days.</li>
</ul>
<h3>What The Experts Say On Stryker</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $360.0.</p>
<ul>
<li>In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $360. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Stryker options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Stryker Unusual Options Activity

<p>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 20 years by 2.97% on an annualized basis producing an average annual return of 11.01%. Currently, Stryker has a market capitalization of $134.77 billion. </p>
<p><strong>Buying $1000 In SYK:</strong> If an investor had bought $1000 of SYK stock 20 years ago, it would be worth <strong>$8,138.94</strong> today based on a price of $354.41 for SYK at the time of writing.</p>
<h3>Stryker's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1710432018_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,100 Today

<p>On March 11, it was revealed in an SEC filing that <strong>William E. Berry, Jr.</strong>, VP at <strong>Stryker</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) executed a significant exercise of company stock options.</p>
<p><strong>What Happened:</strong> A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000310764/000031076424000025//Archives/edgar/data/310764/000031076424000025/0000310764-24-000025-index.htm">U.S. Securities and Exchange Commission</a> on Monday revealed that Jr., VP at Stryker in the Health Care sector, exercised stock options for 19,140 shares of SYK stock. The exercise price of the options was $111.85 per share.</p>
<p>The Tuesday morning update indicates <strong>Stryker</strong> shares down by 1.4%, currently priced at $350.61. At this value, Jr.'s 19,140 shares are worth $4,569,975.</p>
<h3>Delving into Stryker's Background</h3>
<p>Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.</p>
<h3>A Deep Dive into Stryker's Financials</h3>
<p><strong>Positive Revenue Trend:</strong> Examining Stryker's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>11.78%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Analyzing Profitability Metrics:</strong></p>
<ul>
<li>
<p><strong>Gross Margin:</strong> The company excels with a remarkable gross margin of <strong>63.68%</strong>, indicating superior cost efficiency and profitability compared to its industry peers.</p>
</li>
<li>
<p><strong>Earnings per Share (EPS):</strong> The company excels with an EPS that surpasses the industry average. With a current EPS of <strong>3.01</strong>, Stryker showcases strong earnings per share.</p>
</li>
</ul>
<p><strong>Debt Management:</strong> Stryker's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.7</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><strong>Insights into Valuation Metrics:</strong></p>
<ul>
<li>
<p><strong>Price to Earnings (P/E) Ratio:</strong> The P/E ratio of <strong>43.1</strong> is lower than the industry average, implying a discounted valuation for Stryker's stock.</p>
</li>
<li>
<p><strong>Price to Sales (P/S) Ratio:</strong> A higher-than-average P/S ratio of <strong>6.66</strong> suggests overvaluation in the eyes of investors, considering sales performance.</p>
</li>
<li>
<p><strong>EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization):</strong> With an EV/EBITDA ratio lower than industry averages at <strong>29.42</strong>, Stryker could be considered undervalued.</p>
</li>
</ul>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><a href="https://www.schwab.com/brokerage?aff=XEC"><em>Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</em></a></p>
<h3>The Impact of Insider Transactions on Investments</h3>
<p>Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.</p>
<p>Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.</p>
<p>The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.</p>
<p>However, insider sells may not always signal a bearish view and can be influenced by various factors.</p>
<h3>Deciphering Transaction Codes in Insider Filings</h3>
<p>Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A <strong>P</strong> in Box 3 indicates a purchase, while <strong>S</strong> signifies a sale. Transaction code <strong>C</strong> signals the conversion of an option, and transaction code <strong>A</strong> denotes a grant, award, or other acquisition of securities from the company.</p>
<p><a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000310764"><strong>Check Out The Full List Of Stryker's Insider Trades.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insider Trades

Options Exercise: William E. Berry, Jr. At Stryker Realizes $4.57M

<p><strong>Stryker's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) short percent of float has fallen 12.03% since its last report. The company recently reported that it has <strong>4.18 million shares sold short</strong>, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.32 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Stryker Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709308817_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Stryker has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Stryker's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Stryker's peer group average for short interest as a percentage of float is 3.94%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into Stryker's Recent Short Interest

<p>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 20 years by 3.29% on an annualized basis producing an average annual return of 10.95%. Currently, Stryker has a market capitalization of $132.37 billion. </p>
<p><strong>Buying $1000 In SYK:</strong> If an investor had bought $1000 of SYK stock 20 years ago, it would be worth <strong>$7,914.84</strong> today based on a price of $348.11 for SYK at the time of writing.</p>
<h3>Stryker's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708623017_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Stryker 20 Years Ago Would Be Worth This Much Today

<p>RBC Capital  analyst Shagun Singh   reiterates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and maintains $360 price target.</p>


Reiteration

RBC Capital Reiterates Outperform on Stryker, Maintains $360 Price Target

<p>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 15 years by 1.96% on an annualized basis producing an average annual return of 15.02%. Currently, Stryker has a market capitalization of $128.81 billion. </p>
<p><strong>Buying $1000 In SYK:</strong> If an investor had bought $1000 of SYK stock 15 years ago, it would be worth <strong>$7,881.28</strong> today based on a price of $339.03 for SYK at the time of writing.</p>
<h3>Stryker's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1707490825_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,900 Today

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stryker (SYK – Research Report), Novartis AG (CH:NOV...

Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Novartis AG (Six Swiss: CH:NOVN) and AstraZeneca (GB:AZN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Shop Apotheke Europe NV (GB:0RJT – Research Report),...

Analysts Offer Insights on Healthcare Companies: Shop Apotheke Europe NV (GB:0RJT), Stryker (SYK) and Novartis AG (Six Swiss: CH:NOVN)

Global Stock leaders for 2030 in Health Tech - UBS

Top 10 best performing S&P 500 health care stocks of 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Agilent (A – Research Report), GlaxoSmithKline (GS...

Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Robotics and related technologies, such as workflow automation products, cloud services, and generative AI technology, have captivated the investing community. They have assisted in leading the overall market higher over this past year especially. Investors are very interested in technology companies focused on innovation and the rollout of brand-new products and services.</p>



<p>With the technology sector booming, it&rsquo;s a perfect time for investors to jump into these robotics companies with a great future ahead of them. These stocks offer robotics technology for varying uses and have the potential for consistent growth. Investors should consider these robotics stocks to start gaining exposure to this developing industry.</p>



<h2>UiPath (PATH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/04/path-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website homepage of UiPath (PATH)."><div>Source: dennizn / Shutterstock.com</div></div><p><strong>UiPath</strong>&nbsp;(NYSE:<a target="_blank" href="https://investorplace.com/stock-quotes/path-stock-quote/"><strong>PATH</strong></a>) operates an automation platform based on robotic and generative AI capabilities. Its services are provided for industries such as financial services, healthcare, telecom, and manufacturing.</p>



<p>Over the past year, its share price has risen by 20%, partly due to improved earnings potential. It beat analyst expectations regarding its most recent earnings release.</p>



<p>On March 13,UiPath released earnings results for the&nbsp;<a href="https://ir.uipath.com/news/detail/330/uipath-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results" target="_blank">fourth quarter</a> of the fiscal year 2024, stating that total revenue increased by 31% year-over-year. A net loss for Q4 FY 2023 was reported at $28 million, and for Q4 FY 2024, it increased to a net income of $34 million. For Q1 FY 2025, UiPAth predicts that total revenue should be within the range of $330 million to $335 million.</p>



<p>On March 26, UiPath&rsquo;s product for the Automation Cloud Public Sector was&nbsp;<a href="https://seekingalpha.com/news/4083677-uipaths-ai-cloud-software-receives-approval-for-us-government-use" target="_blank">approved for use</a> within the U.S. federal government.</p>



<p>Due to UiPath&rsquo;s automation software capabilities,&nbsp;<a href="https://seekingalpha.com/news/4087911-uipath-initiated-at-overweight-due-to-rpa-leadership-position-keybanc" target="_blank">KeyBlanc upgraded its stock rating</a>&nbsp;to overweight and set a price target of $27 per share.</p>



<p>UiPath is a company on the cutting edge of generative AI and robotics technology that is continuing to improve its overall automation platform for users. It could still experience upside potential since it recently became profitable following a rough couple of years from when the robotics stock started trading publicly back in 2021.</p>



<h2>Stryker (SYK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/syk1600-300x169.jpg" alt="The Stryker (SYK) office in Fremont, California."><div>Source: Sundry Photography / Shutterstock.com</div></div><p><strong>Stryker</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/syk-stock-quote/" target="_blank"><strong>SYK</strong></a>) is a healthcare equipment provider that offers a wide range of medical devices, such as orthopedic treatments like joint replacement and other trauma-related surgeries, as well as implants that help treat neurological needs.</p>



<p>On Jan. 30, Stryker reported 2023&nbsp;<a href="https://s22.q4cdn.com/857738142/files/doc_financials/2023/q4/q4-23-earnings-press-release.pdf" target="_blank">fourth quarter</a> earnings with a total revenue increase of 12% and net income more than doubled to more than $1.1 billion year-over-year. Total sales for its Medsurg and neurotechnology segment increased by 12%, and sales for its orthopedic and spine segment grew by 11% within the previously mentioned time period.</p>



<p>On Feb. 7, SYK announced a&nbsp;quarterly dividend of <a href="https://investors.stryker.com/press-releases/news-details/2024/Stryker-declares-a-0.80-per-share-quarterly-dividend/default.aspx" target="_blank">80 cents per share</a>, payable to investors on April 30; this dividend increase represents a 6% jump in dividend yield compared to the previous year. Its annual dividend yield is sitting at 0.95%, with divided growth for the last 14 consecutive years.</p>



<p>Stryker operates a very robust and stable business based on surgical technology that should be on the radar for investors. It provided a solid dividend yield, with its share price increasing by over 15% in the last year and consistently growing over the last several years. Stryker is a robotics stock that could continue to garner huge returns in the coming years.</p>



<h2>Symbotic (SYM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/sym1600-300x169.png" alt="Person holding smartphone with website of US robotics warehouse company Symbotic Inc. on screen with logo. Focus on center of phone display. Unmodified photo. SYM stock"><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Symbotic</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/sym-stock-quote/" target="_blank"><strong>SYM</strong></a>) is an industrial company that primarily manages supply chains in large warehouse facilities. It also provides artificial intelligence software and robotics to improve efficiency within distribution centers.</p>



<p>On Feb. 5, SYM reported earnings for the&nbsp;<a href="https://ir.symbotic.com/news-releases/news-release-details/symbotic-reports-first-quarter-fiscal-year-2024-results" target="_blank">first quarter of fiscal year 2024</a>, stating that total revenue increased by 79% compared to the previous year. For Q1 FY 2023, a net loss of $68 million was reported, and the deficit shrank by 81% to $13 million for Q1 FY 2024. For the second quarter of FY 2024, Symbotic anticipates total revenue to be in the range of $400 million to $420 million.</p>



<p>Over this past year, its share price has risen by 50%, and it has experienced consistent growth since starting to trade publicly in mid-2022.</p>



<p>It is a company that has substantial growth potential due to its highly sought-after products and services, innovative robotics, and generative AI technology. SYM is moving in the right direction towards overall profitability, with its net loss shrinking and revenue projections growing. Symbotic could be a winner for investors looking to jump on board a growing robotics stock.</p>



<p><em>As of this writing, Noah Bolton&nbsp;did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a></em></p>
<div><p>Noah has about a year of freelance writing experience. He&rsquo;s worked with Investopedia dealing with
topics such as the stock market and financial news.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/3-robotics-stocks-to-turn-1000-into-1-million-april-2024/">3 Robotics Stocks to Turn $1000 into $1 Million: April 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Robotics Stocks to Turn $1000 into $1 Million: April 2024

THQ: Collecting A High Yield From Increased Medical Spending

Stryker (SYK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed from Bank of Ame...

Stryker's Resilience Amidst Competitive Pressures Reinforces Buy Rating

Baron Health Care Fund Q1 2024 Shareholder Letter

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>While artificial intelligence may be useful for a variety of purposes &ndash; including asking silly questions we&rsquo;re afraid to pose in real life &ndash; the ultimate end game for digital intelligence could be to advance the human condition, which brings us to medical <a href="https://investorplace.com/industries/technology/artificial-intelligence/">AI stocks</a>.</p>



<p>When conducted in a controlled environment, AI can help accelerate productivity. It stands logically, then, that the innovation can help medical professionals better care for their patients. Indeed, the numbers reflect this trajectory.</p>



<p>According to MarketsandMarkets, the global AI in the healthcare sector may reach a valuation of $20.9 billion by the end of this year. Further, by 2029, the segment <a href="https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html">could be worth $148.4 billion</a>, implying a compound annual growth rate (CAGR) of 48.1%.</p>



<p>It&rsquo;s easily one of the most compelling categories in the equities sector. With that, below are medical AI stocks to consider.</p>



<h2>Stryker (SYK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/syk1600-300x169.jpg" alt="The Stryker (SYK) office in Fremont, California."><div>Source: Sundry Photography / Shutterstock.com</div></div><p>Specializing in the medical device category, <strong>Stryker</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/syk-stock-quote/"><strong>SYK</strong></a>) offers multiple healthcare solutions. These include implants used in joint replacement and trauma surgeries along with surgical equipment and navigation systems. Last year, management announced that it would <a href="https://www.beckersspine.com/spinal-tech/56212-artificial-intelligence-to-be-more-prolific-across-stryker.html">significantly increase its presence</a> in the AI space. By the final quarter of 2023, the company had 23 patents involving digital intelligence.</p>



<p>Notably, these patents focus on improving efficiency and safety in the operating room through innovative technologies. It&rsquo;s no surprise, then, that SYK stock carries a <a href="https://www.tipranks.com/stocks/syk/forecast">moderate buy</a> consensus view. While the average price target of $358.33 may be modest, the most optimistic target calls for $390, implying 19% upside.</p>



<p>Financially, Stryker isn&rsquo;t what you would call the most exciting idea among medical AI stocks. It is, however, consistent, ultimately pulling off a positive earnings surprise of 5.18% in fiscal 2023. For the current fiscal year, experts are looking at earnings per share of $11.85 on revenue of $22.18 billion. That&rsquo;s a decent improvement over last year&rsquo;s results of $10.6 EPS on sales of $20.5 billion.</p>



<h2>Medtronic (MDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mdt-stock-1-300x169.jpg" alt="Medtronic (MDT) sign outside office building representing healthcare stocks"><div>Source: JHVEPhoto / Shutterstock.com</div></div><p>Another medical device specialist, <strong>Medtronic</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/mdt-stock-quote/"><strong>MDT</strong></a>) offers myriad relevancies. It&rsquo;s perhaps best known for its <a href="https://www.medtronic.com/uk-en/healthcare-professionals/products/cardiovascular.html">Cardiovascular Portfolio</a> business, which offers implantable cardiac pacemakers, cardioverter defibrillators and cardiac resynchronization therapy devices. In the AI space, the company is pushing to realize the full potential of personalized healthcare technology. Through innovations such as data analytics, Medtronic can offer superior chronic disease management.</p>



<p>Again, similar to Stryker, Medtronic should not be confused as a particularly exciting idea among medical AI stocks. Rather, the beauty of the business from an investment standpoint is the consistent profitability. Last fiscal year, the company beat all four of its bottom-line targets. The average positive earnings surprise came out to 4.45%.</p>



<p>For the current fiscal year, analysts anticipate EPS of $5.20 on sales of $32.24 billion. That&rsquo;s modest compared to last year&rsquo;s print of $5.29 EPS on sales of $31.23 billion. However, <a href="https://seekingalpha.com/symbol/MDT/earnings/estimates">long-term projections</a> call for revenue to eventually ride up to nearly $41 billion by 2029. Plus, analysts peg shares a consensus moderate buy with a $93.87 price target, projecting almost 17% upside potential.</p>



<h2>Moderna (MRNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/mrna1600-1-300x169.png" alt="Mobile phone with logo of American pharmaceutical company Moderna Inc. (MRNA) on screen in front of website. Focus on center-left of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p>A biotechnology firm made famous for forwarding a vaccine during the Covid-19 crisis, <strong>Moderna</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrna-stock-quote/"><strong>MRNA</strong></a>) discovers, develops and commercializes messenger-RNA therapeutics and vaccines for the treatment of infectious diseases. In addition, it provides solutions in the field of immune-oncology, rare diseases, autoimmune disorders and cardiovascular conditions. In November, management stated that it seeks to <a href="https://www.modernatx.com/media-center/all-media/blogs/moderna-powered-AI">embed AI into every aspect of its organization</a>.</p>



<p>Fundamentally, the move could potentially help accelerate new medical solutions. That makes MRNA stock a name worth watching closely. Analysts generally have high hopes, rating shares a <a href="https://www.tipranks.com/stocks/mrna/forecast#:~:text=The%20average%20price%20target%20for,the%20current%20price%20of%20%24103.78.">consensus moderate buy</a> with a $122.87 average price target. That implies almost 18% upside potential. Further, the high-side target hits $214, projecting almost 105% growth.</p>



<p>On a financial note, the company is still working on its transition away from Covid-19 vaccine sales. Therefore, the projected comparisons are not pretty. By year&rsquo;s end, sales could reach $4.18 billion, which would imply a 39% decrease from last year&rsquo;s print. Nevertheless, the AI directive could boost demand over the long run.</p>



<p>Notably, by 2030, analysts are calling for revenue to <a href="https://seekingalpha.com/symbol/MRNA/earnings/estimates">hit nearly $31 billion</a>. If you have the patience, MRNA could be one of the medical AI stocks to buy.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/medical-ai-could-be-your-ticket-to-riches-3-stocks-to-buy/">Medical AI Could Be Your Ticket to Riches: 3 Stocks to Buy</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>